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An antibody mimetic known as Fab–PEG–Fab (FpF) is a stable bivalent molecule that may have some potential
therapeutic advantages over IgG antibodies due to diﬀerences in their binding kinetics as determined by surface
plasmon resonance. Here we describe the thermodynamic binding properties to vascular endothelial growth
factor (VEGF) of the FpF antibody mimetics derived from bevacizumab and ranibizumab. Bevacizumab is an
IgG antibody and ranibizumab is an antibody fragment (Fab). Both are used clinically to target VEGF to inhibit
angiogenesis. FpFbeva displayed comparable binding aﬃnity (KD) and binding thermodynamics (DH ¼ 25.7
kcal mole1 and DS ¼ 14 kcal mole1) to bevacizumab (DH ¼ 25 kcal mole1, DS ¼ 13.3 kcal mole1).
FpFrani interactions with VEGF were characterised by large favourable enthalpy (DH ¼ 42 kcal mole1) and
unfavourable entropy (DS ¼ 31 kcal mole1) changes compared to ranibizumab (DH ¼ 18.5 kcal mole1 and
DS ¼ 6.7 kcal mole1), which being a Fab, is mono-valent. A large negative entropy change resulting in
binding of bivalent FpF to homodimer VEGF might be due to the conformational change of the ﬂexible
regions of the FpF upon ligand binding. Mono-valent Fab (i.e. ranibizumab or the Fab derived from
bevacizumab) displayed a larger degree of freedom (smaller unfavourable entropy) upon binding to
homodimer VEGF. Our report describes the ﬁrst comprehensive enthalpy and entropy compensation analysis
for FpF antibody mimetics. While the FpFs displayed similar thermodynamics and binding aﬃnity to the full
IgG (i.e. bevacizumab), their enhanced protein stability, slower dissociation rate and lack of Fc eﬀector
functions could make FpF a potential next-generation therapy for local tissue-targeted indications.Introduction
IgG antibodies are widely used medicines that can have high
aﬃnity for a specic biological epitope. IgGs are bivalent with two
Fabs that are each able to bind to the target epitope. High aﬃnity
is achieved by (i) the inherent binding of the complementary
determinant region (CDR) in each Fab and (ii) the cooperative
binding that is possible because there are two Fabs in an IgG
antibody (i.e. avidity).1 The IgG is bivalent due to the presence of
the 2 Fabs, which are essentially linked together through the
antibody hinge region as if each Fab is bound at the end of linear
molecule (Fig. 1). The cooperative binding of the two Fabs in an
IgG is achieved by the exibility provided in the hinge.1,2
Using a site-selective conjugation strategy to chemically
modify Fabs in the region where they are naturally bound to the
hinge provided the means to make Fab–PEG–Fab (FpF) mole-
cules that are IgG mimetics.3 FpFs derived from IgG Fabs haveLondon, UK. E-mail: h.khalili@uel.ac.uk;
(NIHR) Biomedical Research Centre at
Trust, UCL Institute of Ophthalmology,
ague, Czech Republic. E-mail: sll225@
hemistry 2018been found to have enhanced stability with comparable aﬃnity
to the parent IgG. Improved stability is important to formulate
more concentrated solutions to decrease the frequency of dose
administration.4,24 Interestingly FpFs tend to display a slower
dissociation rate as determined by surface plasmon resonance
(SPR) studies compared to IgG molecules, which could have
important therapeutic advantages.3
FpFs are prepared from the PEG-di(bis-sulfone) 1 which
undergoes site-specic disulde rebridging conjugation with
the accessible Fab disulde (Fig. 1). The FpFs are derived from
bevacizumab and from ranibizumab which target anti-
vascular endothelial growth factor (VEGF). Ranibizumab is
a Fab and is clinically approved to treat wet age related
macular degeneration (AMD) which is one of the main causes
of blindness in the elderly. AMD is characterised by the over
expression of VEGF which causes angiogenesis in the back of
the eye resulting in loss of retinal function.27 Bevacizumab is
an IgG that is targeted to VEGF, but is labelled for systemic
parenteral use to treat cancer. Bevacizumab is clinically used
oﬀ label to treat AMD. Inhibition and neutralization of VEGF is
the most eﬀective way to treat wet AMD and has revolutionised
the treatment of neovascular and vascular permeability
disorders of the retina.5
One advantage of the FpF as a IgG antibody mimetic is that
there is no fragment crystallizable region (Fc). The Fc region in fullRSC Adv., 2018, 8, 35787–35793 | 35787
Fig. 1 Synthetic route to make FpFbeva from bevacizumab. Fabbeva was obtained by papain enzymatic digestion of bevacizumab and puriﬁed using
protein A and ion-exchange chromatography (IEC). The accessible interchange disulﬁde in the Fabbeva was then reduced by DTT and conjugated with
PEG-di(bis-sulfone) 1. Each bis-sulfone moiety in reagent 1 undergoes site-speciﬁc conjugation with the two cysteine thiols from a disulﬁde bond by
a sequence of addition–elimination reactions to insert a stable 3-carbon methylene bridge between the two thiols of the original disulﬁde bond.
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View Article OnlineIgG antibodies can act to cause eﬀector functions and recycling,
which are not required in some applications (e.g. opthalmic). IgGs
are taken up by the retinal pigment epithelium cells (RPE) through
binding of Fc to Fc-receptor (FcRn) to accelerate IgG elimination
from the back of the eye.6–9 Inducing eﬀector functions precludes
the use of antibodies to treat acute inammatory conditions in
ocular tissue. Oen the causes of serious inammation are not
known, so using a medicine that might cause additional inam-
mation must be avoided. Another important attribute of FpF
antibody mimetics is the replacement of the hinge region with the
exible PEG and rebridged disuldes in the FpF molecule which
are more stable than the hinge disulde and single chain peptide
chains that make up the IgG hinge region. The hinge region in
a IgG is susceptible to degradation and disulde scrambling.
Molecules that are designed from long duration of action (e.g. 2
months) must be physicochemically stable.
Isothermal titration calorimetry (ITC) is used extensively to
study ligand–macromolecule interactions in solution.10
Protein–protein studies dominate, but many types of interac-
tions have been examined, e.g. protein–DNA, protein–lipid and
protein–carbohydrate.11 ITC is an eﬀective method to quantify
the thermodynamic changes in solution that are associated with
the binding interactions specic to antibody–antigen complex-
ation, which typically progresses via an enthalpy driven process.
We have previously shown3 that FpFs displayed similar
binding aﬃnity (KD) to a full IgG using enzyme-linked immu-
nosorbent assay (ELISA) and surface plasmon resonance (SPR)
analysis. However, the KD derived from ELISA and SPRmethods
require either the ligand or the antibody to be immobilized
which limits the ability to obtain a thermodynamic prole of the
binding interactions.25 ITC allows the study of both the anti-
body and ligand in solution which is where the in vivo interac-
tions of a circulating ligand with an antibody occur.11,25 In this
paper we determine the thermodynamic parameters of an anti-
VEGF FpF using ITC. These experiments reveal fundamental
information on the mechanism of interaction and stoichiom-
etry of binding12 between the FpF and its soluble ligand. It is not
possible to determine the thermodynamic parameters using35788 | RSC Adv., 2018, 8, 35787–35793SPR and ELISA techniques. Since the FpFs are derived from
a much larger molecular weight, non-peptide linking molecule
(PEG) compared to how the Fabs are linked together in an IgG
(hinge), we wanted to understand what the entropic costs to FpF
binding would be.
Binding interactions can involve an enthalpy driven process
which involves formation of favourable interactions at the
molecular recognition interface and an entropy driven process
which involves the release of surface bound solvent molecules at
the molecular recognition interface.12,13 In some cases, a binding
process can be both enthalpy and entropy driven. We aimed to
use ITC to disentangle these thermodynamic processes to better
understand the binding interactions between an IgG and FpF in
solution. Our data indicate that the IgG hinge region and the FpF
linker do not change the thermodynamic prole for binding to
VEGF. This is quite remarkable considering the structural
diﬀerences between IgGs and FpFs. More interestingly, when the
FpF was synthesised from ranibizumab (a Fab), a larger unfav-
ourable entropy resulted in FpFrani compared to ranibizumab
suggesting a tighter binding for FpF to VEGF.
Results
Binding thermodynamics of antibody mimetic to VEGF is
enthalpy driven
Titration of VEGF with the anti-VEGF FpF antibody mimetics
caused an exothermic reaction (Fig. 2) with the derived thermo-
dynamic parameters. The raw heat data and binding isotherm in
Fig. 2 showed that the binding interaction between the FpFs and
VEGF was an enthalpy driven process, which was probably
induced by van der Waals interactions.14 A 1 : 1 binding model
was applied as the data was best tted to a one-set-of-sites model.
The high-aﬃnity interaction of the bevacizumab derived
antibody mimetic (FpFbeva) with VEGF was exothermic as shown
in Fig. 2. Table 1 summarised the thermodynamic parameters
(DH, TDS and stoichiometry) for bevacizumab, Fab derived
from bevacizumab and FpFbeva measured at 25 C. As with
IgGs,13–15 the FpF binding was characterised by favourableThis journal is © The Royal Society of Chemistry 2018
Fig. 2 Representative data from an lTC experiment. Panel (a) shows the raw heat data obtained over a series of injections. Panel (b) shows
a binding isotherm created by plotting the areas under the peaks in panel against themolar ratio of ligand added tomacromolecule present in the
cell.
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View Article Onlineenthalpy (DH ¼ 25.7 kcal mole1) and unfavourable entropy
(TDS ¼ 14 kcal mole1) as shown in Table 1. Bevacizumab
displayed a DH ¼ 25 kcal mole1 and TDS ¼ 13.3 kcal
mole1. The binding stoichiometry between FpFbeva/IgG and
homodimer VEGF was measured as a 1 to 1 complex indicating
one molecule of FpF/IgG was to bind to one molecule of VEGF.
To compare the diﬀerences between thermodynamic
binding of bivalent IgG/FpFs and monovalent Fabs, the ther-
modynamic interaction of free Fabbeva with VEGF was evaluated
and found to be enthalpy driven and exothermic. DataTable 1 ITC thermodynamic parameters for bevacizumab, Fabbeva and
FpFbeva. All ITC experiments were carried out at 25 C and samples
were dialysed against PBS pH 7.4 buﬀer
At 25 C DH (kcal mole1) TxDS (kcal mole1) N
Bevacizumab 25 13.3 0.46
Fabbeva 12 2.3 0.76
FpFbeva 25.7 14 0.55
This journal is © The Royal Society of Chemistry 2018presented in Table 1 showed the favourable enthalpy (DH¼12
kcal mole1) and unfavourable entropy (TDS ¼ 2.3 kcal
mole1) of Fabbeva were about 2 times for DH and 5 times for
TDS smaller than thermodynamic parameters reported for full
IgG/antibody mimetic.
The stoichiometry of binding between mono-valent Fab and
homodimer VEGF was determined as 2 molecules of Fabs
needed to bind to 1molecule of VEGF. Binding stoichiometry of
an interaction could imply useful information to conrm
protein activity and specicity.12,26 The contrasts with the
binding thermodynamics of bivalent FpFbeva/IgGbeva compared
to the binding thermodynamics of monovalent Fabbeva was also
shown in the binding interaction of bivalent FpF derived from
monovalent Fabrani (ranibizumab) as shown in Table 2.
Table 2 shows that while thermodynamic interactions of
Fabrani (ranibizumab) with VEGF was exothermic and enthalpy
driven with DH ¼ 18.5 kcal mole1 and TDS ¼ 6.7 kcal
mole1, FpFrani displayed about 2 times larger favourableRSC Adv., 2018, 8, 35787–35793 | 35789
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View Article Onlineenthalpy of DH ¼ 42 kcal mole1 and about 5 times larger
unfavourable entropy of TDS ¼ 31 kcal mole1.Binding aﬃnities for IgG and FpFs by ITC
Table 3 lists the comparative aﬃnity values obtained from
diﬀerent techniques used to measure protein–protein interac-
tions. The KD values obtained previously3 from SPR and ELISA
techniques suggested that bevacizumab (KDSPR ¼ 1.33 nM,
KDELISA ¼ 0.08 nM) and FpFbeva (KDSPR ¼ 1.54 nM, KDELISA ¼
0.11 nM) displayed similar binding aﬃnity toward VEGF which
is consistent to what we obtained from ITC experiments in this
work (bevacizumab KDITC¼ 2.3 nM, FpFbeva KDITC¼ 2.1 nM). As
expected, monovalent Fabbeva displayed lower binding aﬃnity
than bivalent antibody in all three techniques.Fig. 3 Representative SDS-PAGE for solutions after ITC analysis.
Novex bis–tris 4–12% gel stained with colloidal blue for protein. M:
standard protein markers, lane 1: VEGF (Mw ¼ 36 kDa), lane 2: anti-
VEGF Fabrani, lane 3: ITC solution of reaction between VEGF and
Fabrani, lane 4: prepared FpFrani, lane 5: ITC solution of reaction
between VEGF and FpFrani (40 mM), lane 6: ITC solution of reaction
between VEGF and FpFrani (20 mM), lane 7: ITC solution of reaction
between VEGF and control Fab (40 mM).Non-covalent solution binding between FpF and VEGF
The binding interactions between the anti-VEGF antibodies and
antibody mimetics with VEGF was visualised by SDS-PAGE.
Fig. 3 shows the SDS-PAGE stained with colloidal blue for
solutions of VEGF (lane 1), Fabrani before ITC (lane 2), Fabrani
aer reacting with VEGF (upon completion of the ITC experi-
ment, lane 3), FpFrani before ITC (lane 4), FpFrani aer reacting
with VEGF (upon completion of the ITC experiment, lanes 5 and
6), and control Fab (non VEGF binder) aer ITC analysis (lanes
7). Results (Fig. 3) illustrate the non-covalent binding that
occurred when VEGF was titrated with one of the anti-VEGF
molecules. For example, as a result of formation of hydrogen
bond or van der Waals bond between Fabrani (50 kDa) and VEGF
(38 kDa), the band in line 3 was observed at about 90 kDa
molecular weight at the saturation phase in ITC experiment.
Similar binding interactions were observed for FpFrani with
molecular weight of 106 kDa (Fig. 3, lane 4) being titrated with
VEGF to show the molecular weight of an approximately 140
kDa (Fig. 3, lanes 5 and 6) at saturation with VEGF. More FpF-
VEGF complex was formed when 1 equivalent of VEGF was
titrated with FpF (compare lanes 5 and 6). No bond was formed
when VEGF was titrated with control, non-VEGF binding Fab as
shown in lane 7.Table 2 ITC thermodynamic parameters for ranibizumab and FpFrani.
All ITC experiments were carried out at 25 C and samples were dia-
lysed against PBS pH 7.4 buﬀer
At 25 C DH (kcal mole1) TxDS (kcal mole1) N
Ranibizumab 18.5 6.7 1.09
FpFrani 42 31 0.44
Table 3 KD comparison from ITC, SPR, and ELISA assays
Sample KD (nM) ITC KD (nM) SPR KD (nM) ELISA
Bevacizumab 2.3 1.33 0.08
Fabbeva 13.9 4.2 0.32
FpFbeva 2.1 1.54 0.11
35790 | RSC Adv., 2018, 8, 35787–35793Discussion
The strength of protein–protein binding is inversely related to the
magnitude of the equilibrium dissociation constant, KD. We
have previously determined binding aﬃnity (KD) and associa-
tion, dissociation rate constants (ka and kd) of FpF and analogous
Fc-fusion mimetics (RpR) against VEGF using SPR.3,20 A RpR is
a Fc-fusionmimetic that, in this case combines the VEGF binding
moieties of aibercept through a PEG linking molecule. RpRs
address the stability issues that Fc-fusion protein share with
IgGs. RpRs displayed greater overall aﬃnity (KD) than Fc fusion.
While binding aﬃnity of FpFs was shown to be similar to IgGs,
the FpFs displayed slower dissociation rate constants (KD), which
would allow FpF to remain in tissue longer than IgGs.
Fabs are linked together in an IgG through relatively short
single peptide chains on each heavy chain through the hinge
disuldes. In contrast for the FpF, the Fabs are linked through
a PEG molecule of 6 kDa. The molecular structures linking the
Fabs in an IgG and FpF are very diﬀerent. Since the Fab CDR
structure is the same in both the IgG (bevacizumab) and
FpFbeva, ITC studies are necessary for us to try to understand the
impact of the linker molecular structure between the two Fabs.
While SPR provides information about the kinetics for binding
interactions, ITC provides information about the thermody-
namics in solution where these IgG and FpFs function. SPR data
can be obscured by mass transfer interactions. Since the Fab
linking structures of the IgG and FpF are diﬀerent, ITC was
required to ensure the binding data obtained by SPR was not
inuenced by mass transfer eﬀects.
ITC is established in life science as ‘gold standard’ and the
only method to directly measure binding enthalpy as well asThis journal is © The Royal Society of Chemistry 2018
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View Article Onlinebinding stoichiometry. Unlike SPR, ITC determine binding
thermodynamic and binding aﬃnity of antibody to the corre-
sponding ligand while both binding partners are in the solution,
so no immobilization or chemical modications are needed. The
chemical modication which sometimes are necessary to deter-
mine binding aﬃnity in SPR, can potentially interfere or aﬀect
binding aﬃnity. In the work described by Bostrom et al.29 an
antibody mimetic against HER2, called bH1, displayed similar
binding aﬃnity as trastuzumab (anti-HER-2 antibody) using SPR,
but diﬀerent binding thermodynamics (enthalpy and entropy)
using ITC. The interaction of bH1 with the HER2 epitope was
entropy driven, whereas binding of trastuzumab to HER2 was
enthalpy driven. This information obtained from ITC was
important to understand that bH1 has strong structural plasticity
resulting in a large favourable entropy change. Such information
is helpful to understand the mechanism of interaction to aid the
development of new antibody-based medicines.
An increase in entropy in protein binding is due to the
release of trapped water molecules from proteins into the bulk
solvent resulting in more degrees of freedom for water molecule
in the bulk compare to the motion restricted water molecules
on the protein surfaces.16,17 However, release of water molecules
from a protein at the binding interface may also result in
structural rearrangements such as the closure of hydrophilic
cavities and release of bound water from the binding interface.17
Binding of bevacizumab and FpFbeva to VEGF is driven by
enthalpy which is greater than the entropic cost (Fig. 4). While
they displayed similar Gibbs energy, the favourable enthalpy
observed was a main driving force for forming a complex
between anti-VEGF antibody or antibody mimetic and VEGF
ligand.
Unfavourable entropy is thought to be a result of confor-
mational change at binding interface leading to a lower degree
of freedom for the formed complex. For example, Seroussi et al.
used ITC to investigate the structure activity relationships ofFig. 4 Overview summarising thermodynamic parameters of anti-VEG
displayed similar Gibbs energy, the favourable enthalpy observed was am
antibody mimetic and VEGF ligand.
This journal is © The Royal Society of Chemistry 2018diﬀerent anti-VEGF cyclic peptides. Results from alanine
mutation demonstrated that the binding aﬃnity was lost for the
isomer with the lowest positive entropy change.28 Larger
entropic compensation and less degree of movement was
observed in the anti-VEGF FpFrani binding to VEGF compared to
ranibizumab suggesting that when one Fab in FpF is bound to
VEGF dimer, the other Fab would bind to the same VEGF dimer
while ranibizumab as a monovalent Fab has more degrees of
movement for binding to a diﬀerent VEGF ligand. This result
suggested that FpFrani comprising of two ranibizumab Fabs
would tightly bind to VEGF. Consideration that dissociation
rate of ranibizumab is exceptionally slow,18 an FpF derived
from ranibizumab would be an exceptionally tight binding
molecule.
Data obtained from SPR,3 suggests there is similar binding
aﬃnity but slower dissociation rate constant for antibody
mimetic (FpFbeva, FpFrani) compare to the parent native anti-
body (bevacizumab, ranibizumab). Slower dissociation rates are
therapeutically important to ensure that once bound to
a ligand, an antibody does not in eﬀect become a slow releasing
depot for that ligand. It also oﬀers a viable strategy to increase
eﬃcacy by increasing the residence time within the target
tissue.19 One reason that ranibizumab has been such
a successful drug is because its dissociation rate is exceptionally
slow, can only be measured with diﬃculty.19 Hence, slower
dissociation rate and larger unfavourable entropy could suggest
a potential for development of longer lasting antibody mimetics
which require less frequent of dosing.
In order to design a new therapeutic drug and engineer new
antibody mimetics, more complete understanding of the
interactions between antibody and its target epitope are
necessary. Insight leading to better therapeutic design does not
simply occur by knowing the binding aﬃnity. A full thermody-
namic analysis to determine enthalpy, entropy, binding stoi-
chiometry of interaction, are required to provide theF molecules. While anti-VEGF antibodies and antibody mimetic (FpF)
ain driving force for forming a complex between anti-VEGF antibody or
RSC Adv., 2018, 8, 35787–35793 | 35791
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View Article Onlineinformation related to a molecular force at binding interface
between antibody and the ligand.Experimental
Materials
Bevacizumab (Avastin®, 25 mg mL1, Genentech) and ranibi-
zumab (Lucentis®, 10 mg mL1, Genentech) were obtained as
clinical leover. hVEGF165 was purchased from Peprotech.
Slide-A-Layzer dialysis cassette kit, 3.5 K MWCO, 0.5 mL was
purchased from ThermoFisher scientic. Phosphate buﬀered
saline (PBS; 0.16 M NaCl, 0.003 M KCl, 0.008 M Na2HPO4 and
0.001 M KH2PO4) was prepared with tablets purchased from
Oxoid.Methods
Fabbeva was obtained by the enzymatic digestion of bev-
acizumab using immobilized papain as described previously.3
Puried Fabbeva was isolated from the digestion mixture using
a Protein A column and then buﬀer-exchange to PBS buﬀer
using Slide-A-Layzer dialysis cassette with 3.5k cut oﬀ overnight
at 4 C.
Fabbeva (2.4 mg mL
1, 6.0 mg in 2.5 mL PBS, pH 7.3) was
incubated with dithiothreitol (DTT) (1.0 mg mL1, 2.5 mg) at
ambient temperature without shaking for 30 min. DTT was then
removed by elution over a new PD-10 column, and the protein
was buﬀer exchanged into the conjugation buﬀer (20 mM
sodium phosphate, 10 mM EDTA, pH 7.4). PEG-di(bis-sulfone) 1
(0.9 eq, 6 kDa) was added (1.08 mg) to the reduced Fabbeva
solution (6.0 mg in 3.3 mL). The solution was incubated at
ambient temperature for approximately 3 h without shaking.
FpFbeva was puried using a single step HiTrap Macrocap SP
cation exchange column (IEC-Macrocap SP, 5.0 mL). The
concentration of the puried FpFbeva was calculated by micro
BCA assay using bevacizumab as standard. Similar procedures
were applied to prepare FpFrani using Fabrani for conjugation
with PEG-di(bis-sulfone) 1.
ITC measurements were performed in a MicroCal™ iTC200
with 200 mL sample cell at 25 C. Extra care was taken when
preparing the samples for ITC experiments as impurities can
signicantly aﬀect the experiment. All ITC samples including
VEGF165 (4 mM, 250 mL), and the titrants (20 mM bevacizumab,
40 mM Fabbeva, 20 mM FpFbeva, 40 mM Fabrani and 20 mM FpFrani)
had to dialyzed against PBS (pH 7.4) using Slide-A-Layzer dial-
ysis cassette with 3.5k cut oﬀ for overnight at 4 C. The titrants
were placed in the syringe, and 2 mL aliquots were injected
incrementally into the sample cell containing VEGF165 (4 mM,
250 mL) at duration of 4 s, spacing of 200 s while stirring at
1000 rpm. Titration of PBS to PBS and VEGF to PBS were used as
a control. The correction was applied on the baseline for the
heat of dilution in the sample due to addition of the sample by
subtracting the integrated peak area from an estimated
constant number which was derived from the plot between the
molar ration of titrant versus titrand. The binding stoichiometry
(N), aﬃnity (KD), binding constant (KB) and enthalpy change
(DH) were determined by tting the data using the “one-set-of-35792 | RSC Adv., 2018, 8, 35787–35793sites” independent binding model21–23 provided by MicroCal
soware. KD¼ 1/KB; DG¼ RT ln KD, where R is the gas constant
(8.315 J K1 mol1) and T is the absolute temperature. DS values
were obtained by calculation using the equation TDS ¼ DH 
DG.
Conclusions
Using ITC enabled us to study the mechanism of interaction
between anti-VEGF antibody mimetics (FpF) synthesised from
bevacizumab and ranibizumab to circulating VEGF. In conclu-
sion, while anti-VEGF antibody mimetic FpFbeva displayed
similar binding aﬃnity (KD) and binding thermodynamics (DH,
DS) as bevacizumab, FpFrani showed to have larger favourable
enthalpy and unfavourable entropy than ranibizumab.
The results suggest that the antibody mimetics, are highly
exible and undergoes a conformational change combined with
signicant interface de-solvation upon binding to VEGF. These
physicochemical properties of FpF enable the requirements for
antibody binding which is a primary factor underlying its
antigenic potential.
Antibody mimetics such as FpFs have potential for next
generation therapies because of their enhanced protein
stability, the lack of Fc eﬀector function, and high binding
aﬃnity and binding thermodynamics with large unfavourable
entropy. In particular there is potential to develop FpFs for
intraocular use to treat blinding conditions such as wet age
macular degeneration (AMD) eye.
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